# Lyell Immunopharma

> This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most

---


## Pages

- [Home Page](https://www.lyell.com/)
- [Privacy Policy](https://www.lyell.com/privacy-policy/)
- [About](https://www.lyell.com/about/)
- [Leadership](https://www.lyell.com/about/leadership/)
- [Science](https://www.lyell.com/science/)
- [Resource Library](https://www.lyell.com/science/resource-library/)
- [Pipeline](https://www.lyell.com/pipeline/)
- [Cell Therapy](https://www.lyell.com/cell-therapy/)
- [Careers](https://www.lyell.com/careers/)
- [Job Openings](https://www.lyell.com/careers/job-openings/)
- [Contact](https://www.lyell.com/contact/)
- [Cookie Policy](https://www.lyell.com/cookie-policy/)
- [Access Policy](https://www.lyell.com/access-policy/)
- [Site Map](https://www.lyell.com/site-map/)

---


## Resources

- [Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial](https://www.lyell.com/resource/chimeric-antigen-receptor-t-cells-targeting-cd19-and-gcc-in-metastatic-colorectal-cancer-a-nonrandomized-clinical-trial/)
- [CD62L Enrichment Achieves Robust Expansion and Memory Phenotype Post-Infusion in Patients with LBCL Treated with Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Candidate](https://www.lyell.com/resource/cd62l-enrichment-achieves-robust-expansion-and-memory-phenotype-post-infusion-in-patients-with-lbcl-treated-with-rondecabtagene-autoleucel-an-autologous-dual-targeting-cd19-cd20-car-t-cell-candidate/)
- [LYL314, a CD19/CD20 CAR T-Cell Candidate Enriched for CD62L+Stem-Like Cells, Achieves High Rates of Durable Complete Responses in R/R Large B-Cell Lymphoma](https://www.lyell.com/resource/lyl314-a-cd19-cd20-car-t-cell-candidate-enriched-for-cd62lstem-like-cells-achieves-high-rates-of-durable-complete-responses-in-r-r-large-b-cell-lymphoma/)
- [Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Candidate Manufactured from CD62L+ Enriched T Cells, Achieves Durable Responses in Patients with Large B-Cell Lymphoma](https://www.lyell.com/resource/rondecabtagene-autoleucel-an-autologous-dual-targeting-cd19-cd20-car-t-cell-candidate-manufactured-from-cd62l-enriched-t-cells-achieves-durable-responses-in-patients-with-large-b-cell-lymphoma/)

---